Buy Curosurf® suspension 80 mg/ml 1.5 ml vials 1 pc.

Curosurf® [Poractant alfa]

Brand Chiesi Pharmaceutical SpA

In stock 1836 Items

Available since: 2019-09-19

All payments are SSL encrypted
Full Refund if you haven't received your order
International shipping to the USA, UK and Europe

Clinical Pharmacology

Curosurf® has a surfactant-like effect.

Indications

Respiratory distress syndrome (hyaline membrane disease) in premature newborns weighing more than 700 g.

Composition

1 ml contains paracant alpha (phospholipid fraction isolated from pig lungs) 80 mg (composition per 1 ml suspension: the phospholipid fraction isolated from pig lungs is 80 mg / ml, equivalent to approximately 74 mg / ml of the total concentration of phospholipids and 0.9 mg low molecular weight hydrophobic proteins).

No customer reviews for the moment.

Write your review

Dosage and Administration

The drug is prescribed IV the drip, in the form of a slow infusion. Single dose - 1-2 ampoules, if necessary, you can re-enter after 4-6 hours. To prepare a solution for intravenous infusion, the contents are 1-2 amp. dissolved in 50-100 ml of 5% glucose solution.

Adverse reactions

With rapid on / in the introduction may develop symptoms of hyperkalemia and / or hypermagneemia.

Contraindications

- Acute and chronic renal failure.
- Oliguria, anuria.
- Addison's Disease.
- AV blockade II and III degree.
- Cardiogenic shock (BP <90 mm="" hg="" br="">- Hyperkalemia.
- Hypermagnesemia.
- Hypersensitivity to the drug.

Drug interactions

With simultaneous use with potassium-sparing diuretics (triamterene, spironolactone), beta-blockers, cyclosporine, heparin, ACE inhibitors, NSAIDs, the risk of hyperkalemia increases up to the occurrence of arrhythmia and asystolia. The use of potassium preparations together with the corticosteroids eliminates the hypokalemia they cause. Under the influence of potassium, a decrease in the undesirable effects of cardiac glycosides is observed.
The drug enhances the negative dromo and bathmotropic action of antiarrhythmic drugs.
Due to the presence of potassium ions in the composition of the drug when using Panangin with ACE inhibitors, beta-blockers, cyclosporine, potassium-sparing diuretics, heparin, NSAIDs, hyperkalemia may develop (potassium plasma levels must be controlled); with anticholinergics - a more pronounced decrease in intestinal motility; with cardiac glycosides - reducing their action.
Magnesium preparations reduce the effectiveness of neomycin, polymyxin B, tetracycline and streptomycin.
Anesthetics increase the inhibitory effect of magnesium on the central nervous system. When using Panangin with atracurium, dexametonium, suxametonium, an increased neuromuscular blockade is possible; with calcitriol - an increase in the level of magnesium in the blood plasma; with calcium preparations, a decrease in the action of magnesium ions is observed.
With the simultaneous use of Panangin with potassium-sparing diuretics and ACE inhibitors increases the risk of hyperkalemia (should monitor the level of potassium in the plasma).

Pregnancy and Lactation

Data on the negative effects of the drug in the form of a solution for IV injection during pregnancy and lactation (breastfeeding) are not available.

Special instructions

It should be carefully prescribed the drug to patients with an increased risk of developing hyperkalemia. In this case, it is necessary to regularly monitor the level of potassium ions in the blood plasma. Before taking the drug, the patient should consult a doctor. With rapid on / in the introduction of the drug may develop redness of the skin.
Application for violations of kidney function: The drug is contraindicated in the following cases - acute and chronic renal failure, oliguria, anuria.
Influence on ability to drive motor transport and control mechanisms: the drug does not affect the ability to drive and engage in activities that require high concentration of attention and speed of psychomotor reactions.

Overdosage

Symptoms: with a / in the introduction - hyperkalemia, hypermagnesia.
Treatment: drug withdrawal, symptomatic therapy (IV the introduction of 100 mg / min of calcium chloride solution), if necessary, hemodialysis and peritoneal dialysis.